Results 11 to 20 of about 196,019 (232)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia[S] [PDF]

Journal of Lipid Research, 2014
Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. However, reduction is transient, indicating that the long-term cardiovascular benefits of apheresis may not solely be due to LDL removal. Microparticles (MPs)
Katherine D. Connolly, Gareth R. Willis, Dev B.N. Datta, Elizabeth A. Ellins, Kristin Ladell, David A. Price, Irina A. Guschina, D. Aled Rees, Philip E. James   +8 more
doaj   +3 more sources

LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection

Journal of Lipid Research, 2011
Subnormal HDL-cholesterol (HDL-C) and apolipoprotein (apo)AI levels are characteristic of familial hypercholesterolemia (FH), reflecting perturbed intravascular metabolism with compositional anomalies in HDL particles, including apoE enrichment. Does LDL-
Alexina Orsoni, Samir Saheb, Johannes H.M. Levels, Geesje Dallinga-Thie, Marielle Atassi, Randa Bittar, Paul Robillard, Eric Bruckert, Anatol Kontush, Alain Carrié, M. John Chapman   +10 more
doaj   +2 more sources

LDL‐aférese no tratamento de hipercolesterolemia familiar: experiência do Hospital Santo António

Revista Portuguesa de Cardiologia, 2015
Resumo: Introdução: A hipercolesterolemia manifestada pelos níveis elevados de colesterol das lipoproteínas de baixa densidade constitui um fator de risco major para o desenvolvimento e progressão da doença aterosclerótica prematura.A adsorção direta de
Isabel Palma, Ana Rita Caldas, Isabel Mangas Palma, José Alexandre Queirós, Anselmo Madureira, José Carlos Oliveira, Paulo Palma, Carlos Correia, Maria Helena Ramos   +8 more
doaj   +2 more sources

Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia

Journal of Lipid Research, 2012
In familial hypercholesterolemia (FH), low HDL cholesterol (HDL-C) levels are associated with functional alterations of HDL particles that reduce their capacity to mediate the reverse cholesterol transport (RCT) pathway.
Alexina Orsoni, Elise F. Villard, Eric Bruckert, Paul Robillard, Alain Carrie, Dominique Bonnefont-Rousselot, M. John Chapman, Geesje M. Dallinga-Thie, Wilfried Le Goff, Maryse Guerin   +9 more
doaj   +2 more sources

The Pathological Role of LDL in Membranous Nephropathy and Diabetic Nephropathy and the Protective Efficacy of LDL Apheresis: A Narrative Review [PDF]

Toxins
Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease worldwide. One-third of patients with DN develop primary glomerulonephritis, and membranous nephropathy (MN) is the most common concurrent glomerulonephritis.
Goh Kodama, Kensei Taguchi, Yusei Wada, Kaoru Nakano, Ryo Shibata, Kei Fukami   +5 more
doaj   +2 more sources

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia [PDF]

Lipids in Health and Disease, 2011
Background Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between inflammation and cardiovascular disease, and thus is a suitable target for therapeutic strategy against cardiovascular disease.
Minichilli Fabrizio, Bigazzi Federico, Sbrana Francesco, Puntoni Mariarita, Ferdeghini Ezio, Sampietro Tiziana   +5 more
doaj   +2 more sources

Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics & Systems Pharmacology
Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH).
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +8 more
doaj   +2 more sources

LDL Apheresis and Inflammation – Implications for Atherosclerosis

Scandinavian Journal of Immunology, 2012
AbstractLow‐density lipoprotein (LDL) apheresis is an extracorporeal treatment modality used in high‐risk patients when LDL cholesterol levels cannot be reduced adequately with medication. The treatment is highly effective, but could be affected by potential unwanted effects on pro‐ and anti‐inflammatory biomarkers.
A. Hovland, K. Lappegård, T. Mollnes
semanticscholar   +3 more sources

Outpatient monthly plasmapheresis with post-PLEX evinacumab in pediatric homozygous familial hypercholesterolemia: a case report on port access and immunoglobulin preservation [PDF]

Frontiers in Pediatrics
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein (LDL) cholesterol levels, predisposing patients to early cardiovascular disease.
Guido Filler, Kambiz Norozi, Kambiz Norozi   +2 more
doaj   +2 more sources

Real-World Safety Data From the World Apheresis Association Registry for the Spectra Optia Apheresis System. [PDF]

J Clin Apher
ABSTRACT In this study we analyzed 12 years of adverse events, (AE) data from the World Apheresis Association, (WAA) Registry specific to the Spectra Optia Apheresis System. We queried WAA Registry data, (2012–2023) on apheresis procedures performed exclusively on the Spectra Optia Apheresis System.
Haubner A, Mendoza S, Vrielink H, Witt V, Deeren D, Bojanic I, Gasova Z, Aandahl A, Glatt TN, Vasilache AM, Newman E, Strineholm V, Skosana Y, Stegmayr B.   +13 more
europepmc   +2 more sources